We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash
Read MoreHide Full Article
Key Takeaways
Edwards Lifesciences' Q3 EPS rose 8.1% year over year, topping consensus by 13.6%.
EW's sales grew 14.8% to $1.55 billion, led by strong TAVR and TMTT segment performance.
EW's gross and operating margins fell sharply amid higher costs and expense growth.
Edwards Lifesciences Corporation (EW - Free Report) reported third-quarter 2025 adjusted earnings per share (EPS) of 67 cents, which surpassed the Zacks Consensus Estimate by 13.6%. The figure increased 8.1% from the year-ago quarter’s level.
One-time adjustments primarily include certain litigation expenses and amortization of intangible assets.
GAAP EPS from continuing operations was 50 cents, which remained flat on a year-over-year basis.
Edwards’ Q3 Sales Details
Sales totaled $1.55 billion, up 14.8% year over year. The metric surpassed the Zacks Consensus Estimate by 3.3%.
Following the earnings announcement, EW stock rose 1.9% in aftermarket trading yesterday.
EW Q3 Sales by Segments
Transcatheter Aortic Valve Replacement (“TAVR”)
Global sales in the product group amounted to $1.15 billion, up 12.4% year over year or 10.6% at constant currency (CER). This compares with our model’s projection of $1.11 billion for the quarter.
In Europe, the exit of a competitor resulted in a rebalancing of the market and a modest contribution to Edwards’ sales. In Japan, TAVR sales growth continues to improve, reflecting a gradual recovery in market growth.
Transcatheter Mitral and Tricuspid Therapies (“TMTT”)
Sales totaled $145.2 million, up 59.3% from the prior-year figure on a reported basis. This compares with our model’s projection of $134.1 million.
This performance was driven by increased adoption and balanced contribution from PASCAL and EVOQUE in the United States, Europe and globally.
Surgical Structural Heart
The segment delivered sales of $258 million, up 7.5% from the year-ago level on a reported basis and 5.6% at CER. This compares with our model’s projection of $256.7 million.
This growth was driven by the strong global adoption of Edwards Lifesciences’ premium RESILIA tissue portfolio, specifically the INSPIRIS, MITRIS and KONECT devices.
Edwards’ Q3 Margin Performance
The gross profit was $1.21 billion, up 10.7% year over year. The gross margin contracted 282 basis points (bps) to 77.8% due to a 31.3% increase in cost of sales.
SG&A expenses rose 22.1% year over year to $514.6 million. R&D expenditures amounted to $280.7 million, up 10.8% year over year.
The operating income decreased 1% year over year to $412.6 million. The operating margin contracted 420 bps to 26.6%.
EW’s Cash Position
The company exited the third quarter with cash and cash equivalents of $3.00 billion compared with $3.00 billion at the end of the second quarter of 2025. Total debt remained sequentially consistent at approximately $600 million.
Edwards Lifesciences Corporation Price, Consensus and EPS Surprise
Edwards is increasing its full-year total company sales growth guidance to the high end of 9% to 10%. The Zacks Consensus Estimate for sales is pegged at $5.99 billion, suggesting a 0.3% increase from the 2024 level.
The company now expects 2025 adjusted EPS to be between $2.56 and $2.62. The Zacks Consensus Estimate for the same is pegged at $2.51.
For the fourth quarter of 2025, EW projects total sales to be in the band of $1.51 and $1.59 billion and adjusted EPS in the 58-64 cents range. The Zacks Consensus Estimate for fourth-quarter sales and EPS is pinned at $1.54 billion and 60 cents, respectively.
Our Take
Edwards Lifesciences beat on both earnings and revenues in the third quarter of 2025. TAVR growth in the quarter was better than expected as clinicians demonstrated a renewed focus on prioritizing treatment for patients suffering from aortic stenosis. Within TMTT, PASCAL’s distinct features are driving distinguished clinical outcomes, along with higher adoption at both new and existing sites around the world.
Additionally, SAPIEN M3 mitral valve replacement system’s CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio. In Surgical, Edwards made progress, advancing important innovations globally, such as the KONECT aortic valved conduit that received CE Mark approval in Europe.
On the flip side, contraction of both margins in the quarter is highly discouraging.
The company’s commitment to driving breakthrough innovations in pioneering and leading categories bodes well. Given the strong third-quarter performance, Edwards is confident about its 2025 outlook.
EW’s Zacks Rank and Key Picks
Edwards Lifesciences currently carries a Zacks Rank #3 (Hold).
Veracyte reported second-quarter 2025 adjusted EPS of 44 cents, which beat the Zacks Consensus Estimate by 41.9%. Revenues of $130.2 million topped the Zacks Consensus Estimate by 7.1%. VCYT currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 19.3% for 2025 compared with the industry’s 12.9%. The company beat on earnings in each of the trailing four quarters, the average surprise being 242.77%.
Phibro Animal Health, currently carrying a Zacks Rank #1, reported a fourth-quarter fiscal 2025 EPS of 57 cents, which beat the Zacks Consensus Estimate by 9.62%. Net sales of $378.7 million topped the consensus estimate by 4.86%.
Phibro has an estimated earnings growth rate of 21.1% for fiscal 2026 compared with the industry’s 12.8%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%.
Insulet, currently sporting a Zacks Rank #2 (Buy), reported a second-quarter 2025 adjusted EPS of $1.17, which outperformed the Zacks Consensus Estimate by 25.81%. Revenues of $649.1 million exceeded the Zacks Consensus Estimate by 5.46%.
PODD has an estimated earnings growth rate of 42.3% for 2025 compared with the industry’s 12.7%. The company beat on earnings in each of the trailing four quarters, the average surprise being 19.54%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash
Key Takeaways
Edwards Lifesciences Corporation (EW - Free Report) reported third-quarter 2025 adjusted earnings per share (EPS) of 67 cents, which surpassed the Zacks Consensus Estimate by 13.6%. The figure increased 8.1% from the year-ago quarter’s level.
One-time adjustments primarily include certain litigation expenses and amortization of intangible assets.
GAAP EPS from continuing operations was 50 cents, which remained flat on a year-over-year basis.
Edwards’ Q3 Sales Details
Sales totaled $1.55 billion, up 14.8% year over year. The metric surpassed the Zacks Consensus Estimate by 3.3%.
Following the earnings announcement, EW stock rose 1.9% in aftermarket trading yesterday.
EW Q3 Sales by Segments
Transcatheter Aortic Valve Replacement (“TAVR”)
Global sales in the product group amounted to $1.15 billion, up 12.4% year over year or 10.6% at constant currency (CER). This compares with our model’s projection of $1.11 billion for the quarter.
In Europe, the exit of a competitor resulted in a rebalancing of the market and a modest contribution to Edwards’ sales. In Japan, TAVR sales growth continues to improve, reflecting a gradual recovery in market growth.
Transcatheter Mitral and Tricuspid Therapies (“TMTT”)
Sales totaled $145.2 million, up 59.3% from the prior-year figure on a reported basis. This compares with our model’s projection of $134.1 million.
This performance was driven by increased adoption and balanced contribution from PASCAL and EVOQUE in the United States, Europe and globally.
Surgical Structural Heart
The segment delivered sales of $258 million, up 7.5% from the year-ago level on a reported basis and 5.6% at CER. This compares with our model’s projection of $256.7 million.
This growth was driven by the strong global adoption of Edwards Lifesciences’ premium RESILIA tissue portfolio, specifically the INSPIRIS, MITRIS and KONECT devices.
Edwards’ Q3 Margin Performance
The gross profit was $1.21 billion, up 10.7% year over year. The gross margin contracted 282 basis points (bps) to 77.8% due to a 31.3% increase in cost of sales.
SG&A expenses rose 22.1% year over year to $514.6 million. R&D expenditures amounted to $280.7 million, up 10.8% year over year.
The operating income decreased 1% year over year to $412.6 million. The operating margin contracted 420 bps to 26.6%.
EW’s Cash Position
The company exited the third quarter with cash and cash equivalents of $3.00 billion compared with $3.00 billion at the end of the second quarter of 2025. Total debt remained sequentially consistent at approximately $600 million.
Edwards Lifesciences Corporation Price, Consensus and EPS Surprise
Edwards Lifesciences Corporation price-consensus-eps-surprise-chart | Edwards Lifesciences Corporation Quote
Edwards’ 2025 & Q4 Guidance
Edwards is increasing its full-year total company sales growth guidance to the high end of 9% to 10%. The Zacks Consensus Estimate for sales is pegged at $5.99 billion, suggesting a 0.3% increase from the 2024 level.
The company now expects 2025 adjusted EPS to be between $2.56 and $2.62. The Zacks Consensus Estimate for the same is pegged at $2.51.
For the fourth quarter of 2025, EW projects total sales to be in the band of $1.51 and $1.59 billion and adjusted EPS in the 58-64 cents range. The Zacks Consensus Estimate for fourth-quarter sales and EPS is pinned at $1.54 billion and 60 cents, respectively.
Our Take
Edwards Lifesciences beat on both earnings and revenues in the third quarter of 2025. TAVR growth in the quarter was better than expected as clinicians demonstrated a renewed focus on prioritizing treatment for patients suffering from aortic stenosis. Within TMTT, PASCAL’s distinct features are driving distinguished clinical outcomes, along with higher adoption at both new and existing sites around the world.
Additionally, SAPIEN M3 mitral valve replacement system’s CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio. In Surgical, Edwards made progress, advancing important innovations globally, such as the KONECT aortic valved conduit that received CE Mark approval in Europe.
On the flip side, contraction of both margins in the quarter is highly discouraging.
The company’s commitment to driving breakthrough innovations in pioneering and leading categories bodes well. Given the strong third-quarter performance, Edwards is confident about its 2025 outlook.
EW’s Zacks Rank and Key Picks
Edwards Lifesciences currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Phibro Animal Health (PAHC - Free Report) and Insulet (PODD - Free Report) .
Veracyte reported second-quarter 2025 adjusted EPS of 44 cents, which beat the Zacks Consensus Estimate by 41.9%. Revenues of $130.2 million topped the Zacks Consensus Estimate by 7.1%. VCYT currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 19.3% for 2025 compared with the industry’s 12.9%. The company beat on earnings in each of the trailing four quarters, the average surprise being 242.77%.
Phibro Animal Health, currently carrying a Zacks Rank #1, reported a fourth-quarter fiscal 2025 EPS of 57 cents, which beat the Zacks Consensus Estimate by 9.62%. Net sales of $378.7 million topped the consensus estimate by 4.86%.
Phibro has an estimated earnings growth rate of 21.1% for fiscal 2026 compared with the industry’s 12.8%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%.
Insulet, currently sporting a Zacks Rank #2 (Buy), reported a second-quarter 2025 adjusted EPS of $1.17, which outperformed the Zacks Consensus Estimate by 25.81%. Revenues of $649.1 million exceeded the Zacks Consensus Estimate by 5.46%.
PODD has an estimated earnings growth rate of 42.3% for 2025 compared with the industry’s 12.7%. The company beat on earnings in each of the trailing four quarters, the average surprise being 19.54%.